Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial*
Daniel P. Schuster(University of Freiburg), John P. Pribble(Apple (Israel)), Eileen Coyne(Washington University in St. Louis), Sonia Souza(Stellenbosch University), S. C. Lowry(University of Kent), Gus J. Slotman(Apple (Israel)), Howard Levy(Apple (Israel)), R.A. Balk(Apple (Israel)), Michael H. Metzler(Washington University in St. Louis), Edward Abraham(New York Medical College), Steven M. Opal(Brown University)
Cited by 82
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Intensive Care Medicine|2003|2.9k